Biotherapies in large vessel vasculitis

Abstract

The mainstay of therapy of large vessel vasculitides (LVV) remains glucocorticoids (GC). Although most patients initially achieve disease remission, relapses and GC dependence are seen in more than two-thirds of cases. Conventional synthetic disease-modifying antirheumatic drugs (DMARDs) showed little or no steroid sparing effects, while biological agents represent a valid therapeutic option in patients with severe and/or relapsing LVV.

Keywords: Biological therapies; Biotherapies; Giant cell arteritis; Large vessel vasculitis; Takayasu arteritis.